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Converting enzyme inhibition and progressive glomerulosclerosis in the
rat. The effect of converting enzyme inhibition (CE!) by captopril
(CAP, 500 mg/liter drinking water) on the development and progression
of glomerulosclerosis (OS) was studied in six groups of male unine-
phrectomized (UN) Wistar rats. In group A, treated with CAP for four
to five weeks after UN, a reduction in systolic blood pressure (SEP),
filtration fraction and glomerular volumes was found as compared to
control group B. Long—term treatment with CAP for eight months after
UN (group C) resulted in lowering of SBP with 30 mm Hg, a low level
of proteinuria and low incidence of GS (0 to 1.5%) as compared to
control rats (group D), with SBP of 131 4 mm Hg, proteinuria up to
103 to 509 mg/day and 9.1 to 29.7% OS at eight months after UN.
Oroups E and F were followed without therapy up to seven months
after UN, at which time a high level of proteinuria was present. CAP
therapy then started in group B, did not reduce SBP, proteinuria and OS
at 11 months after UN relative to control group F. This study shows
that early CE! prevents progressive proteinuria and GS in rats after UN
and is associated with a reduction in SBP, filtration fraction and
glomerular volume. Once high levels of proteinuria and OS have
developed in rats after UN, CE! has no effect on SBP nor on the
progression of OS and proteinuria.
Progressive glomerulosclerosis (GS) develops spontaneously
with aging in several rat strains [1—5], a process which can be
accelerated by a reduction in renal mass [6—11], by high protein
feeding [12—141, by streptozotocin-induced diabetes mellitus
[15] and by desoxycorticosterone-salt induced hypertension
[16]. In addition, progressive GS may develop in chronic amino-
nucleoside nephrosis [17] and adriamycin nephrosis [181. Sev-
eral pathogenetic mechanisms have been shown to be relevant
as to the development of the glomerular lesions, which resem-
ble focal segmental glomeruloscierosis in man. Based on a
number of recent studies using micropuncture and morphologic
techniques, a central role in the pathogenesis of progressive GS
has been attributed to elevated intraglomerular pressures and
flows [14, 19, 20], resulting in a process of endothelial, epithelial,
and mesangial cell damage [21]. Besides these hemodynamic
factors, genetic [221, metabolic [23] and coagulation [24, 251
factors have been shown to be important in the development of
GS. In several models of progressive OS dietary or pharmaco-
logical intervention has been applied to retard or prevent
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glomerular disease. Protein restriction was found to have a
beneficial effect in ablation models [11, 26], in experimental
diabetes [27] and hypertension [16]. Anti-coagulatory drugs
were also effective in models of ablation [24, 25] and hyperten-
sion [28].
In the remnant kidney model linoleic acid, a prostaglandin
precursor [29], and lipid lowering agents [30] were found to
have an ameliorative effect. Antihypertensive treatment using
converting enzyme inhibitors, introduced shortly after the
induction of glomerular hyperperfusion was remarkably effec-
tive in reducing OS in the remnant kidney model [31] and in
streptozotocin-induced diabetes mellitus [32]. Recently, Meyer
et al showed that reversal of glomerular hypertension either by
converting enzyme inhibition or by protein restriction stabilized
established glomerular injury in the remnant kidney model [331.
The remnant kidney model is a model of subtotal ablation, in
which one kidney is removed and two thirds of the remaining
kidney are infarcted. This model is associated with systemic
hypertension, which develops soon after ablation.
The present study was designed to test the efficacy of convert-
ing enzyme inhibition on the development and progression of
glomeruloscierosis in a less extreme model of renal ablation
without development of systemic hypertension. For this pur-
pose, male Wistar rats were subjected to unilateral nephrec-
tomy and captopril treatment was started either immediately or
at seven months after nephrectomy, at which time increased
levels of proteinuria and glomerulosclerosis had developed.
Methods
Six groups of three months old, male Wistar rats with an
initial body weight of 210 to 245 g were subjected to unilateral
nephrectomy (UN) under ether anesthesia (Fig. 1). The rats
were fed ad libitum with a standard chow (Hope Farms Inc.,
Woerden, the Netherlands) containing 0.22% sodium and 26%
digestible protein.
Groups A, C, and E were treated with the angiotensin I
converting-enzyme inhibitor captopril (Squibb, Rijswijk, the
Netherlands) in a dose of 500 mg/liter in the drinking water (Fig.
1). Administration of captopril was started the day after UN in
groups A and C and at seven months after UN in group E.
Groups B, D, and F received no therapy (control groups). Renal
function and glomerular volumes were determined at four to
five weeks after UN in group A (N = 6) and group B (N 8).
Rats in group C (N 12) and group D (N = 11) were followed
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for eight months after UN during which time body weight,
systolic blood pressure and urinary protein excretion were
monitored. Systolic blood pressure was measured weekly in
awake, trained rats by the tail cuff method [34]. Urinary protein
excretion was measured monthly by the biuret method in urine
collected by housing the rats for 24 hours in metabolic cages
with free access to water and food. Serum levels of cholesterol
and triglycerides were measured according to standard methods
in blood obtained at the end of the observation period after a
24-hour period of fasting. At sacrifice after perfusion-fixation,
kidneys were processed for histology. Rats of group E (N =6)
and F (N = 7) were followed for seven months after UN without
therapeutic intervention. At seven months after UN, protein-
uria had increased to 115 to 536 mg/24 hr in group E and to ill
to 407 mg/24 hr in group F. Body weight curves were similar.
Captopril treatment (500 mg/liter) was then introduced to group
E and both groups were followed for another four months with
monthly determination of body weight and urinary protein loss.
At 7 and 11 months after UN, creatinine clearances were
determined based on creatinine concentration measured in
serum and the amount of excreted creatinine in a 24-hour urine
collection.
At sacrifice 11 months after UN, systolic blood pressure was
recorded by arterial cannulation under mactin anesthesia (100
mg/kg) and after perfusion-fixation the kidneys were processed
for histology.
Renal function and glomerular volumes
GFR and RPF were determined as described before [35]. Rats
of groups A and B were anesthetized with mactin (Byk Gulden,
Konstanz, Germany), 100 mg/kg i.p., and placed on a heated
operating table. Body temperature was kept between 37°C and
38°C, monitored by a rectal thermometer (Telethermometer,
Yellow Springs, Colorado, USA). After tracheostomy, two
polyethylene catheters PE10 (Clay Adams, Parsipanny, New
Jersey, USA) were inserted in the left jugular vein for infusion
of inulin and serum. The right femoral artery was cannulated
with a PE5O polyethylene catheter connected to a pressure
transducer (Western Lab, model 91, Colorado, USA) and
systolic blood pressure (SBP) was recorded. The left ureter was
cannulated with a PEIO catheter. Forty minutes prior to the
clearance period, a 4% inulin solution (Sigma Chemical Co., St.
Louis, Missouri, USA) was given as a bolus of 0.5 ml, followed
by a constant infusion at a rate of 0.034 ml/min. In addition a
bolus of 0.2 ml serum was given, followed by infusion at a rate
of 0.020 mi/mm for replacement of fluid loss. The clearance rate
of inulin was determined during two consecutive periods of 20
minutes during which time urine was collected from the left
kidney. Arterial blood was obtained by continuous withdrawal
from the femoral artery for the coincident 40 minutes (Harvard
pump model 4-940). A 0.2 ml sample of renal venous blood was
obtained at the end of the second clearance period. Hematocrits
were measured in arterial blood samples obtained at the end of
the second clearance period. The concentration of inulin in
urine and plasma samples was measured by the anthrone
colorimetric assay [36]. GFR and RPF were calculated accord-
ing to standard formulas.
At the end of the second clearance period, the kidney was
fixed by perfusion at the measured arterial pressure with 1%
glutaraldehyde in 0.1 M phosphate buffer, pH 7.4. Renal tissue
was postfixed in 4 g% buffered formaldehyde solution and
processed for morphometric analysis through methacrylate
embedding. Two micron sections were stained with silver
methenamine. Fifty systematically sampled glomeruli were
traced along the Bowman's capsule and along the glomerular
tuft profile over the surface of a graphic tablet morphometric
analyzer (MOP-AMO3, Kontron, Echingen, FRG) connected to
a Digital PDP1 1 computer (Digital Equipment Inc., Gaiway,
Ireland). Mean glomerular capsular volume (GVc) was calcu-
lated as described by van Damme and Koudstaal [37] from the
mean glomerular radius using the formula 4/3ir r3. The average
glomerular tuft volume (GVT) was calculated as GVT /3/k.
(A312), where A is the mean glomerular random cross-sectional
area, /3 is 1.38, the shape coefficient for spheres (the idealized
shape of glomeruli) and k is 1.1, a size distribution coefficient
[31, 38].
Histology
The kidneys of rats in groups C, D, E and F were fixed by
perfusion and processed for light microscopy as described
above. Sections were stained with periodic acid-Schiff (PAS).
Glomeruli were counted with overt sclerotic lesions, defined as
glomerular lesions consisting of subendothelial and mesangial
deposition of hyalin material, increase of mesangial matrix and
collapse of glomerular capillaries with adhesions of the tuft to
Bowman's capsule. The incidence of GS lesions was deter-
mined by scoring at least 100 glomeruli in a coronal section of
each kidney.
Statistics
Statistical analysis was performed by Student's t-test for
comparisons between the means of two groups. The Mann-
Whitney test was used to compare levels of urinary protein
excretion and the incidence of glomerular lesions between
groups C and D and between groups E and F. Statistical
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Fig. 1. Design of the study, depicting the groups of rats, uninephrec-
tomized at 3 months of age. Symbols are: () Captopril treatment; ()
no treatment.
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GFR RPF FF Hct
mi/mm %
A 6 292 17 105 12 1.92 0.24 8.81 1.81 22.1 2.3a 47.0 0.8
B 8 302 13 128 5 1.95 0.23 7.35 1.33 27.1 4.7 47,5 1.9
Values are mean SD. Abbreviations used in this table: BW, body weight; SBP, systolic blood pressure; GFR, glomerular filtration rate; RPF,
renal plasma flow; FF, filtration fraction; Hct, hematocrit.
a Student's t-test, P <0.05 group A vs. group B
Results
Short term study
Renal function and glomerular volumes. Mean values for
body weight (body wt), systolic blood pressure (SBP), glomer-
ular filtration rate (GFR), renal plasma flow (RPF), filtration
fraction (FF), and hematocrit (Hct) for groups A and B are
summarized in Table 1. Body wt did not differ in the two
groups, averaging 292 17 g in group A and 302 13 gin group
B. SBP was significantly lower in the captopril-treated animals
than in the control animals (105 12 mm Hg vs. 128 5 mm
Hg, P < 0.05). Mean values for GFR were almost identical in
both groups, averaging 1.92 0.24 mllmin in group A and 1.95
0.23 mI/mm in group B. Compared to age- and sex-matched,
two-kidney control rats studied previously [35], GFR was
approximately 1.8-fold higher after UN. In captopril-treated
animals, RPF was not significantly higher than in control
animals (8,81 1.81 mi/mm vs. 7.35 1.33 ml/min, P> 0.1).
The FF in captopril-treated animals was significantly lower than
in untreated animals (22.1 2.3% vs. 27.1 4.7%, P < 0.05).
Hct did not differ in the two groups.
As described above, the kidneys of rats of groups A and B
were fixed by perfusion at the measured SBP. To compare data
on glomerular volumes with previous data in the same strain
[35] and with data from other studies, both average glomerular
capsular and tuft volumes were determined. As shown in Table
2, the average glomerular capsular and tuft volumes were
significantly higher in the untreated rats (GVc: 2.14 0.39 X
106 pm3; GVT: 1.80 0.24 x 10 m3) than in the captopril-
treated anImals (GVc: 1.43 0.18 x 106 msm3; GVT: 1.15 0.14
x 106 pm3). In untreated rats of group B, GVc was close to the
value documented in a previous study [351. To determine
whether the difference in perfusion pressure could account for
the disparity in mean glomerular volume, kidneys of additional
captopril-treated animals were perfused at 100 mm Hg (N =3)
or at 130 mm Hg (N = 3). The difference in perfusion pressure
was found to have no effect on the mean glomerular capsular
and tuft volume.
Long-term studies: Early captopril treatment
As measured by the tailcuff method, untreated control rats of
group D remained normotensive throughout the eight months
observation period (129 5 mm Hg at S months after UN; 131
4 mm Hg at 8 months after UN). SBP in captopril-treated rats
of group C was significantly lower than SBP in the control group
D (101 3 mm Hg at 5 months after UN; 102 3 mm Hg at 8
months after UN) (group C vs. group D, P < 0.05).





A 6 1.43 0.l8a 1.15 0.l4a
B 8 2.14 0.39 1.80 0.24
Values are mean SD
a P < 0.05, group A vs. group B
During the eight-month observation period, captopril treat-
ment did not affect the growth of the animals. Captopril-treated
rats of group C and control rats of group D showed comparable
weight gain (Table 3). At sacrifice rats of group Chad a body wt
of 400 42 g, whereas rats of group D weighed 420 33 g (P
> 0.2).
The untreated control rats of group D developed progressive
proteinuria reaching values of 103 to 509 mg124 hr at eight
months after UN, whereas significantly less proteinuria was
found in the captopril-treated rats of group C with levels of 30
to 49 mg/24 hr (Table 3).
At sacrifice, cholesterol levels were significantly higher in
control animals of group D than in captopril-treated animals of
group C (2.56 0.59 mmollliter vs. 1.90 0.17 mmol/liter, P <
0.05). However, there was no statistical significant difference in
levels of triglycerides in the two groups (control rats: 0.85
0.26 mmol/liter; captopril-treated rats: 0.66 0.24 mmol/liter,
0.05 <P < (110).
In the kidneys of proteinuric untreated rats of group D,
glomeruli were present displaying a spectrum of morphologic
abnormalities as described by Rennke [21]. Mesangial expan-
sion and hypercellularity, epithelial cell swelling and segmental
lesions defined as areas of collapsed capillaries with accumula-
tion of condensed hyalin material and adhesions to Bowman's
capsule were observed (Fig. 2). Tubulointerstitial changes
varied in severity and consisted of tubular dilation as well as
atrophy, protein casts, interstitial edema and patchy mononu-
clear infiltrates. The incidence of segmental glomerulosclerotic
lesions ranged froni 9.1 to 29.7% (median: 13.0%) in untreated
control rats of group D, whereas in captopril-treated rats of
group C lesions were found in 0 to 1.5% (median:1.0%) of the
glomeruli (P < 0.05) (Fig. 3).
Long-term studies: Late captopril treatment
At seven months after UN, groups E and F had similar body
weights, and body weight curves showed no significant changes
during the following four months when captopril was given to
rats of group E (Table 3).
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Table 3. Body weights and urinary protein excretion in groups C, D, E, and F
Group N
Body weight g Urinary protein excretion mg/24 hr
at UN
at7mo
after UN at sacrificeal at UN
atlmo













































Values are mean SD or range (r) with median (m).
a Groups C and D at 8 months after UN
b Groups E and F at 11 months after UN
C Mann-Whitney test, P <0.05 group C vs. group D
Fig. 2. Light micrograph of renal cortex
illustrating a representative glomerulus from an
untreated control rat from group F showing a
glomerular lesion consisting of a segmental
area of collapsed capillaries with accumulation
of condensed hyalin material and adhesions to
the Bowmans capsule (PAS, X 400).
In animals of group E, urinary protein loss increased from 21
to 46 mg124 hr at UN to 115 to 536 mg/24 hr seven months after
UN and increased further during the four months of captopril
treatment to 273 to 883 mg/24 hr at 11 months after UN (Table
3). Untreated rats of group F developed similar levels of
proteinuria with a range of 20 to 45, 111 to 407 and 191 to 721
mg/24 hr at UN, at seven months and at 11 months after UN,
respectively. There was no statistically-significant difference
between groups E and F at all intervals.
At seven months after UN, creatinine clearances were similar
in both groups: 0.47 0.10 mllmin/lOOg body wt in group E and
0.46 0.05 mlJminIlOOg body wt in group F. As compared to
seven months after UN, creatinine clearances determined at 11
month after UN had significantly decreased in both groups,
reaching values of 0.31 0.12 mllmin/100 g body wt and 0.30
0.08 mllmin/l00 g body wt in groups E and F, respectively (P <
0.05). Creatinine clearances at 11 months after UN in the two
groups were not statistically different.
Systolic blood pressures, measured at sacrifice under mactin
anesthesia, were not significantly different between both groups:
129 27 mm Hg in group E and 141 20 mm Hg in group F (P
> 0.10).
At sacrifice at 11 months after UN, glomerular changes in
both group E and group F were more severe than observed in
group D. Both segmental and global glomerulosclerotic lesions
were present, associated with severe tubulointerstitial changes.
No statistically significant differences were observed in the
incidence of glomerulosclerotic lesions reaching values of 15.4
to 87.2% in group E and 12.6 to 68.6% in group F, respectively
(Fig. 3).
Discussion
The present study shows that converting-enzyme inhibition
by captopril prevents the development of progressive GS and
proteinuria in aging uninephrectomized rats when treatment is
started early after UN. When given at a later stage to unine-
phrectomized animals suffering from established GS and pro-
teinuria, captopril neither diminishes nor retards The progres-
sion of proteinuria and GS.
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Fig. 3. Incidence of glomerular lesions (GL) observed at sacrifice in the
captopril-treated groups C and E (•) andcontrol groups D and F (0).
(*) Mann-Whitney U-test, P < 0.05 group C vs. group D; (—) median
value.
The study was performed in male rats of a Wistar strain
known to be susceptible to develop progressive GS spontane-
ously with aging [2, 8]. Unilateral nephrectomy has been shown
to accelerate this process [8, 35]. In the current study, the
remaining kidney of the uninephrectomized untreated rats of
group B showed a compensatory increase in GFR and RPF at
one month after UN and a marked expansion of glomerular
volumes as compared to what we found earlier in two-kidney
animals of this strain [35]. Early treatment with captopril (group
A) markedly reduced systemic blood pressure and the filtration
fraction without affecting GFR, and prevented the increase in
glomerular volume expansion after UN. These findings suggest
a captopril-induced reduction of glomerular transcapillary pres-
sure, similar to what has been found during converting-enzyme
inhibition by enalapril in the remnant kidney model [31, 33] and
in experimental diabetes mellitus [32], two models associated
with elevated intraglomerular flows and pressures. Micropunc-
ture studies in these two models revealed that converting
enzyme inhibition protected the glomerular capillary network
from intracapillary hypertension by reducing systemic blood
pressure and total arteriolar resistance without affecting the
glomerular flow and filtration rate.
Morphometnc analysis in those studies documented an increase
in glomerular volumes in the untreated state of hyperliltration
and a reduction in glomerular volumes during converting en-
zyme inhibition [31, 32]. Long-term treatment with enalapril
markedly ameliorated the development of GS in the remnant
kidney model and in experimental diabetes mellitus. However,
a comparison between the different models of glomerular hy-
perfiltration and GS is difficult because of obvious differences in
systemic and intrarenal hemodynamic and metabolic determi-
nants, and in genetic factors which may play a role in the
susceptibility for progressive GS [22].
A reduction in SBP by approximately 30 mm Hg was ob-
served in the captopril-treated animals of group C of the present
study. The relatively high, systemic blood pressure in untreated
rats of group D could be an important factor in the pathogenesis
of GS, depending on the afferent arteriolar resistance. This level
of SBP by itself does not inevitably cause GS, since rats of the
WKY strain with similar levels of SBP are remarkably resistant
to the development of GS [39]. Moreover, Brandis et al [401
recently described a relative resistance to GS in the spontane-
ously hypertensive Milan strain, in contrast to a high incidence
of GS in the normotensive Milan strain, suggesting that sys-
temic hypertension per se does not have to increase intraglo-
merular pressure or induce progressive GS.As stated earlier by
Baldwin [41] and Brenner [42], afferent vasoconstriction is
crucial in protecting the glomerulus from the systemic blood
pressure. Elevation of intracapillary pressure can be caused by
a disproportional dilatation of the afferent arteriole, which can
occur after high protein intake [10, 14] or renal ablation [10, 31],
and in experimental diabetes mellitus [15, 27] and hypertension
[16, 43]. Other factors possibly involved in the pathogenesis of
progressive GS, such as metabolic changes or coagulation
factors, were not studied by us. Therefore we can not rule out
an effect of converting enzyme inhibition along one of these
lines. Serum cholesterol levels were higher in the proteinuric
animals which may have had an additional effect on the pro-
gression of GS, since lipids are known to accumulate in the
glomerular lesions [44], and lipid lowering agents have been
shown to have a beneficial effect on the development of
progressive GS in obese Zucker rats [45].
The introduction of captopril in proteinuric animals of group
E at seven months after UN did not affect the progression of
proteinuria and glomerular injury when compared to non-
treated control animals. Moreover, a reduction in systemic
blood pressure as observed after early treatment with captopril
was not found in rats of group E. These findings are in contrast
to the study recently published by Meyer et al [33]. They
showed that the introduction of the converting enzyme inhibitor
enalapril eight weeks after 5/6 renal ablation reversed systemic
and glomerular hypertension, prevented a further rise in pro-
teinuria and limited glomerular lesions at 18 weeks relative to
untreated control rats. A similar effect was obtained by dietary
protein restriction. The discrepancy between the study per-
formed by Meyer et al and our study could be due to a number
of differences in (a) the model: the remnant kidney model with
systemic hypertension versus the milder model of unilateral
nephrectomy without hypertension; (b) the time interval be-
tween ablation and intervention; (c) the converting enzyme
inhibitor: enalapril versus captopril; and (d) the strain of rats:
Munich-Wistar strain versus Wistar strain.
The lack of effect of captopril on systemic blood pressure and
glomerular pathology in aging and already proteinuric rats in the
present study may have been caused by several factors. Struc-
tural glomerular changes caused by hyalin deposition, sclerosis,
mesangial cell proliferation and hypertrophy, may have resulted
in a less sensitive target for pharmacological intervention,
similar to what has been described for vascular and renal
changes in advanced stages of systemic hypertension [46]. A
lack of effect of CE! on proteinuria in animals of group E was
not unexpected, since CE! generally leaves GFR and RPF
intact as shown in animals of group A and in studies of the
remnant kidney model [31]. With preservation of GFR and
RPF, proteins will be filtered across the severely damaged
capillary wall to a similar extent as in untreated animals.
Recently, studies on the effect of converting enzyme inhibition
in Adriamycin nephrosis showed that the introduction of a
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converting-enzyme inhibitor, while lowering systemic [47, 481
and intraglomerular [47] pressures did not decrease protein
excretion [47, 48]. However, protein excretion could be re-
duced in this model by dietary protein restriction [48, 491.
A recent study in patients with advanced diabetic nephrop-
athy described a beneficial effect of CEI on urinary protein loss
[50]. In man, protein restriction has already been shown to be
effective in retarding the progression of several forms of chronic
renal failure [51, 52]. A number of prospective clinical trials are
now being carried out to study the effect of CE! on the course
of chronic renal failure in man. Although it is hazardous to
extrapolate findings of experimental models to the clinical
setting, the results of the current study seem to caution for too
optimistic expectations of CEI treatment in chronic renal fail-
ure.
In summary, captopril was found to prevent the development
of GS in uninephrectomized male Wistar rats only when CE!
was started early after UN. Under these circumstances capto-
pril had a profound effect on SBP and renal vascular resistance
as measured one month after UN. Initiation of captopril treat-
ment at a later stage, when GS and proteinuria had already
developed, proved to be ineffective with regard to SBP and the
progression of proteinuria and glomerular lesions.
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